
The SILK Laser Australia Ltd (ASX: SLA) share price is in the red on Thursday morning after the company announced a resilient first-quarter trading update.
At the time of writing, the SILK Laser share price is down 0.75% to $4.61.
SILK Laser share price down as COVID-19 restrictions bite
SILK Laser delivered a resilient performance over the first quarter ended 30 September. Some highlights include:
- Network cash sales adjusted for lost trading days up 14% to $23.5 million;
- Unadjusted network cash sales down 4%;
- Like-for-like sales adjusted for lost trading days up 2% to $20.4 million; and
- Unadjusted like-for-like sales down 14%.
SILK was pleased with its FY22 year-to-date performance considering the lost trading days due to closed clinics during COVID-19 lockdowns. It also comes against the backdrop of an exceptionally strong comparable period last year.
The trading update highlighted strong growth across body and injectable categories, with its overall service mix evolving, as planned.
Online sales for SILK’s skincare brands surged by 700% to about $189,000, although this came off a low base.
Back in September, the company announced it had completed the acquisition of Australian Skin Clinics (ASC), which pushed the SILK Laser share price higher at the time. The company advised the integration of ASC is on track.
ASC’s financial performance was not included in SILK’s Q1 sales metrics given its 4 weeks of ownership.
Management commentary
SILK founder and managing director Martin Perelman commented on the first-quarter results, saying:
We are pleased with how the business has performed over the first three months of FY22. While COVID lockdowns again held back sales growth as clinics were forced to close, on an adjusted basis we saw strong momentum in key growth categories, resulting in overall positive like-for-like sales growth. In particular, SILK experienced strong growth across its body and injectables categories, and exceptional growth in online sales of our skincare brands.
What’s next for SILK?
SILK is positive on its outlook, citing the majority of NSW clinics achieved the equivalent of approximately two weeks’ worth of trading within the first week of opening after lockdowns.
“Cosmetic Injectables, as has happened previously, performed far above expectations driven by strong waitlists and the strength of SILK’s injecting teams.”
Its service and earnings mix is expected to continue to evolve with a growing position in injectable and body categories. SILK said it will continue to roll out these service offerings across its network.
Despite a challenging trading environment so far in 2021, the SILK Laser share price is up 29% year-to-date.
The post SILK Laser (ASX:SLA) share price edges lower on quarterly update appeared first on The Motley Fool Australia.
Should you invest $1,000 in SILK Laser right now?
Before you consider SILK Laser , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and SILK Laser wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- Why is the Flight Centre (ASX:FLT) share price down 6% today?
- Why the Bitcoin (CRYPTO:BTC) price is rocketing to new, all-time highs
- Catapult (ASX:CAT) share price higher on surging annual contract value
- Newcrest (ASX:NCM) CEO reveals the company’s gold, copper and Bitcoin mining plans
- ELMO (ASX:ELO) share price surges 8% on first-quarter update
Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended SILK Laser Australia Limited. The Motley Fool Australia has recommended SILK Laser Australia Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/2Z6BRAF
Leave a Reply